Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 2/20 | 0.63 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 8/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 2/20 | 0.32 |
| ▸ | KYNU | Q16719 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.31 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19157785 | 1.00 | ITGAL (0.63) | ITGALITGB1ITGA5ITGA4SLC16A3 | |
| SCHEMBL19157989 | 0.94 | ITGAL (0.54) | ITGALITGB1ITGA5SLC16A3MEN1 | |
| SCHEMBL13894422 | 0.92 | ITGAL (0.65) | ITGALITGB1ITGA5ITGA4SLC16A3 | |
| SCHEMBL12169844 | 0.92 | ITGAL (0.63) | ITGALITGB1ITGA5ITGA4SLC16A3 | |
| SCHEMBL12054488 | 0.92 | ITGAL (0.62) | ITGALITGB1ITGA5ITGA4SLC16A3 | |
| SCHEMBL19157561 | 0.92 | ITGAL (0.62) | ITGALITGB1ITGA5ITGA4SLC16A3 | |
| SCHEMBL4922611 | 0.92 | ITGAL (0.62) | ITGALITGB1ITGA5ITGA4SLC16A3 | |
| SCHEMBL16726910 | 0.90 | ITGAL (0.49) | ITGALSLC16A3MEN1LMNAKMT2A | |
| SCHEMBL10112626 | 0.90 | ITGAL (0.65) | ITGALITGB1ITGA5ITGA4SLC16A3 | |
| SCHEMBL23153599 | 0.89 | ITGAL (0.64) | ITGALITGB1ITGA5ITGA4SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| EP-3797775-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | NOVARTIS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| EP-3167886-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | NOVARTIS AG (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10188641-B2 | Compositions and methods for treatment | SARCODE BIOSCIENCE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20110165229-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165228-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165229-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009054914-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB1 2/4885ITGA5 7/4885 |
| US-20110165228-A1 | Compositions and Methods for Treatment | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 9/4885 |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB1 2/4885ITGA5 7/4885 |
| US-20110165229-A1 | Compositions and Methods for Treatment | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 9/4885 |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 9/4885 |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 9/4885 |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB1 2/4885ITGA5 7/4885 |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 9/4885 |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 10/4885 |
| US-10188641-B2 | Compositions and methods for treatment | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 9/4885 |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB1 5/4885ITGA5 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.